GAL-1 variants having immuno-modulating properties and methods of using the same

US10000548B2 · kind B2 · utility

Assignees

• CONSEJO NACIONAL DE INVESTIGACIONES CIENTÍFICAS Y TÉCNICAS (CONICET) · AR
• FUNDACIÓN SALES · AR
• INIS BIOTECH LLC · US

Inventors

• Gabriel Rabinovich · Dieciséis de Julio, AR
• Santiago Di Lella · Berlin, DE
• Dario Ariel Estrin · Olavarría, AR
• Julio Javier Carmelo · Olavarría, AR
• Santiago Patricio Mendez Huergo · Distrito Ciudad de Tunuyán, AR

Key dates

• Filing date: Apr 21, 2016
• Grant date: Jun 19, 2018
• Expiry date: Apr 21, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Galectin-1 polypeptide variants that include a mutation of the histidine residue corresponding to position 52 of the full-length amino acid sequence of native human Gal-1 as shown in SEQ ID NO: 1, the mutation being a substitution of the histidine to tyrosine or asparagine, providing resistance to acidosis otherwise resulting in deactivation of the native human Gal-1. The Galectin-1 polypeptide variants may include one or more additional mutation(s) of the cysteine residue corresponding to a position selected from 2, 16, 88, or combinations thereof of the full-length amino acid sequence of native human Gal-1 as shown in SEQ ID NO: 1, the additional mutation being a substitution of the cysteine to serine, and providing resistance to oxidation.